Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine | Zendy

Karen Hager | Zendy; Gonzalo Pérez Marc | Zendy; Philipe Gobeil | Zendy; Ricardo Sobhie Diaz | Zendy; Gretchen Heizer | Zendy; Conrado J. Llapur | Zendy; А. И. Макарков | Zendy; Eduardo Vasconcellos | Zendy; Stéphane Pillet | Zendy; Fernando Riera | Zendy; Pooja Saxena | Zendy; Priscila Geller Wolff | Zendy; Kapil Bhutada | Zendy; Garry Wallace | Zendy; Hessam Aazami | Zendy; Christine E. Jones | Zendy; Fernando P. Polack | Zendy; Luciana Ferrara | Zendy; Judith Atkins | Zendy; Iohann Boulay | Zendy; Jiwanjeet Dhaliwall | Zendy; Nathalie Charland | Zendy; Ma Couture | Zendy; Julia Jiang-Wright | Zendy; Nathalie Landry | Zendy; Sophie Lapointe | Zendy; Aurélien Lorin | Zendy; Asif Mahmood | Zendy; Lawrence H. Moulton | Zendy; Emmy Pahmer | Zendy; Julie Parent | Zendy; Annie Séguin | Zendy; Luan T. Tran | Zendy; Thomas Breuer | Zendy; Maria-Angeles Ceregido | Zendy; Marguerite Koutsoukos | Zendy; François Roman | Zendy; Junya Namba | Zendy; MarcAndré D’Aoust | Zendy; Sonia Trépanier | Zendy; Yosuke Kimura | Zendy; Brian J. Ward | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine

Author(s) -

Karen Hager,

Gonzalo Pérez Marc,

Philipe Gobeil,

Ricardo Sobhie Diaz,

Gretchen Heizer,

Conrado J. Llapur,

А. И. Макарков,

Eduardo Vasconcellos,

Stéphane Pillet,

Fernando Riera,

Pooja Saxena,

Priscila Geller Wolff,

Kapil Bhutada,

Garry Wallace,

Hessam Aazami,

Christine E. Jones,

Fernando P. Polack,

Luciana Ferrara,

Judith Atkins,

Iohann Boulay,

Jiwanjeet Dhaliwall,

Nathalie Charland,

Ma Couture,

Julia Jiang-Wright,

Nathalie Landry,

Sophie Lapointe,

Aurélien Lorin,

Asif Mahmood,

Lawrence H. Moulton,

Emmy Pahmer,

Julie Parent,

Annie Séguin,

Luan T. Tran,

Thomas Breuer,

Maria-Angeles Ceregido,

Marguerite Koutsoukos,

François Roman,

Junya Namba,

MarcAndré D’Aoust,

Sonia Trépanier,

Yosuke Kimura,

Brian J. Ward

Publication year - 2022

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2201300

Subject(s) - medicine , placebo , vaccine efficacy , confidence interval , adjuvant , population , randomized controlled trial , coronavirus , vaccine trial , covid-19 , virology , clinical trial , immunology , disease , vaccination , infectious disease (medical specialty) , pathology , alternative medicine , environmental health

Coronavirus-like particles (CoVLP) that are produced in plants and display the prefusion spike glycoprotein of the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are combined with an adjuvant (Adjuvant System 03 [AS03]) to form the candidate vaccine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research